POLYMORPHS OF ESZOPICLONE MALATE
    6.
    发明申请
    POLYMORPHS OF ESZOPICLONE MALATE 审中-公开
    异黄酮黄酮的多聚体

    公开(公告)号:US20080027223A1

    公开(公告)日:2008-01-31

    申请号:US11690580

    申请日:2007-03-23

    IPC分类号: C07D487/04

    CPC分类号: C07D487/04

    摘要: The present invention provides crystalline Eszopiclone malate form II, crystalline Eszopiclone form V, processes from preparing the crystalline Eszopiclone malate form II or V, pharmaceutical compositions comprising the crystalline Eszopiclone malate form II or V and methods of treating insomnia comprising administering the crystalline Eszopiclone malate form II or V.

    摘要翻译: 本发明提供结晶埃索替普罗苹果酸盐形式II,结晶埃索普洛尔形式V,从制备结晶依佐匹克隆苹果酸盐形式II或V的方法,包含结晶异山梨酸丙酮酸形式II或V的药物组合物和治疗失眠症的方法,包括施用结晶埃索普洛尔苹果酸盐形式 II或V.

    Crystalline rosuvastatin calcium and compositions thereof for treatment of hyperlipidaemia
    7.
    发明授权
    Crystalline rosuvastatin calcium and compositions thereof for treatment of hyperlipidaemia 失效
    结晶罗苏伐他汀钙及其组合物用于治疗高脂血症

    公开(公告)号:US07994178B2

    公开(公告)日:2011-08-09

    申请号:US11901813

    申请日:2007-09-18

    IPC分类号: A61K31/4965

    CPC分类号: C07D239/42

    摘要: The present invention provides a crystalline form of rosuvastatin calcium characterized by an X-ray powder diffraction pattern having peaks at about 4.7, 19.4 and 22.3° 2θ±0.2° 2θ. The crystalline form of the invention may be further characterized by a DSC thermogram with an endotherm at about 132° C. and another broad endotherm at about 220° C. to about 240° C., and a TGA thermogram showing a weight loss of about of 3 to about 5 percent up to about 100° C. The invention also provides a pharmaceutical composition comprising the crystalline rosuvastatin calcium, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

    摘要翻译: 本发明提供了一种结晶形式的瑞舒伐他汀钙,其特征在于X-射线粉末衍射图在约4.7,19​​.4和22.3±2之间具有峰;±0.2°2。 本发明的结晶形式可以进一步表征为具有在约132℃的吸热和约220℃至约240℃的吸热的另一广泛吸热的DSC热分析图,显示出约3至 约5%至约100℃。本发明还提供了包含结晶罗苏伐他汀钙或其药学上可接受的盐和至少一种药学上可接受的赋形剂的药物组合物。

    POLYMORPHS OF FEXOFENADINE HYDROCHLORIDE
    9.
    发明申请
    POLYMORPHS OF FEXOFENADINE HYDROCHLORIDE 审中-公开
    FEXOFENADINE HYDROCHLORIDE的聚合物

    公开(公告)号:US20090012121A1

    公开(公告)日:2009-01-08

    申请号:US12207399

    申请日:2008-09-09

    IPC分类号: A61K31/445 C07D211/34

    CPC分类号: C07D211/22

    摘要: The present invention provides novel crystal forms of fexofenadine hydrochloride Forms V, VI and VIII through XV and processes for their preparation and preparation of amorphous form and other crystalline forms of fexofenadine hydrochloride. Forms XIV and XV are solvates of ethyl acetate, while Form IX is a solvate of MTBE or cyclohexane. The forms are useful for administration to humans and animals to alleviate symptoms caused by histamine. The present invention further provides pharmaceutical compositions of the new crystalline forms.

    摘要翻译: 本发明提供盐酸非索非那定形式V,VI和VIII至XV的新型结晶形式及其制备和制备盐酸非索非那定的无定形形式和其它结晶形式的方法。 形式XIV和XV是乙酸乙酯的溶剂合物,而形式IX是MTBE或环己烷的溶剂合物。 这些形式可用于给予人类和动物以减轻组胺引起的症状。 本发明还提供了新的结晶形式的药物组合物。